Breaking News Instant updates and real-time market news.

MGTA

Magenta Therapeutics

$15.23

0.17 (1.13%)

08:15
01/13/20
01/13
08:15
01/13/20
08:15

Magenta Therapeutics provides update across several programs

Magenta Therapeutics highlighted recent progress across several programs and outlined goals for 2020. Current methods to condition patients before transplant and gene therapy are dependent on toxic, non-specific chemotherapy or radiation. These pre-transplant treatments are associated with significant side effects, including infertility, cancer, organ damage and death. Magenta is developing targeted, disease-modifying ADCs that are designed to precisely and rapidly remove the disease-causing cells in the body and enable immune system reset without the need for chemotherapy or radiation. Magenta's new clinical candidate, MGTA-117, is a CD117 antibody conjugated to amanitin. Results published in an abstract for the Transplant and Cellular Therapy annual meeting show that MGTA-117 depleted stem and progenitor cells and demonstrated a wide tolerability: potency ratio of 30 fold. This program is advancing to the clinic and further validates Magenta's antibody drug conjugate-based conditioning platform. MGTA-117 was developed under a partnership with Heidelberg Pharma that grants Magenta exclusive worldwide development and marketing rights for ADCs using an amanitin payload and targeting CD117. Magenta is scaling up manufacturing of MGTA-117 and completing IND-enabling studies in 2020. The company intends to move this new product candidate into the clinic with initial clinical data expected in 2021. Magenta has identified a lead antibody and has progressed this program into IND-enabling studies, which the company plans to further advance in 2020. Magenta intends to complete the Phase 1 study and move this program into multiple Phase 2 studies in patients in 2020. The Phase 2 studies will include both allogeneic and autologous transplant settings and will evaluate mobilization and collection of high-quality cells and engraftment of the cells after transplant. Magenta intends to complete enrollment in the Phase 2 in 2020 and continue dialogue with the FDA under the RMAT designation, and to discuss with the European Medicines Agency for development in Europe

MGTA Magenta Therapeutics
$15.23

0.17 (1.13%)

03/24/19
GSCO
03/24/19
DOWNGRADE
GSCO
Neutral
Magenta Therapeutics downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs downgraded Magenta Therapeutics to Neutral on valuation.
03/25/19
GSCO
03/25/19
DOWNGRADE
Target $16
GSCO
Neutral
Magenta Therapeutics downgraded to Neutral on valuation at Goldman Sachs
Goldman Sachs analyst Terence Flynn last night downgraded Magenta Therapeutics to Neutral from Buy and lowered his price target for the shares to $16 from $17. The analyst reduced his near-term estimates for MGTA-456 after the company elected to delay initiation of a Phase 2 trial in sickle cell disease. He cites valuation for the downgrade to Neutral with the shares slightly above his new price target.
12/06/19
GSCO
12/06/19
INITIATION
Target $18
GSCO
Neutral
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
Goldman Sachs analyst Paul Choi assumed coverage of Magenta Therapeutics with a Neutral rating with a price target of $18, up from $16. . While encouraged by Magenta's focus on different stages in the transplant process and the curative potential of transplant, the analyst awaits further clinical validation given the mostly early stage nature of its assets.
12/06/19
BTIG
12/06/19
INITIATION
Target $20
BTIG
Buy
Magenta Therapeutics initiated with a Buy at BTIG
BTIG analyst Amanda Murphy initiated coverage of Magenta Therapeutics with a Buy rating and $20 price target. The analyst notes that the company is developing a suite of therapeutic candidates targeting an improved bone marrow transplant process to address key barriers to adoption. Murphy adds that despite the improvement in technology and the growth in bone marrow transplants, about 60% of 150K heme cancer instances eligible for transplant do not receive one.

TODAY'S FREE FLY STORIES

NIO

NIO Inc.

$5.10

0.425 (9.10%)

11:45
01/21/20
01/21
11:45
01/21/20
11:45
Options
NIO call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:42
01/21/20
01/21
11:42
01/21/20
11:42
Conference/Events
JPMorgan agribusiness analysts to hold an analyst/industry conference call »

Food &…

JAZZ

Jazz Pharmaceuticals

$151.11

0.11 (0.07%)

11:39
01/21/20
01/21
11:39
01/21/20
11:39
Conference/Events
Cantor Fitzgerald biopharma analyst to hold analyst/industry conference call »

Biopharma & Specialty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

AIG

AIG

$51.93

-0.95 (-1.80%)

, AON

Aon plc

$211.62

-0.15 (-0.07%)

11:36
01/21/20
01/21
11:36
01/21/20
11:36
Conference/Events
William Blair insurance analyst to hold a luncheon meeting »

Insurance Analyst Klauber…

AIG

AIG

$51.93

-0.95 (-1.80%)

AON

Aon plc

$211.62

-0.15 (-0.07%)

BRO

Brown & Brown

$41.32

-0.095 (-0.23%)

MMC

Marsh & McLennan

$114.27

0.16 (0.14%)

WLTW

Willis Towers Watson

$205.62

0.67 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 28

    Jan

  • 28

    Jan

  • 30

    Jan

  • 31

    Jan

  • 06

    Feb

  • 10

    Feb

  • 11

    Feb

  • 11

    Feb

  • 26

    Feb

TRIP

TripAdvisor

$30.53

-0.38 (-1.23%)

11:35
01/21/20
01/21
11:35
01/21/20
11:35
Options
TripAdvisor put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

11:34
01/21/20
01/21
11:34
01/21/20
11:34
Conference/Events
Stephens life science analyst to hold a group luncheon »

Life Science Tools &…

YARIY

Yara

$0.00

(0.00%)

11:33
01/21/20
01/21
11:33
01/21/20
11:33
Hot Stocks
Yara announces investigation by Spanish competition regulator »

Yara announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALE

Vale

$13.37

-0.275 (-2.02%)

11:29
01/21/20
01/21
11:29
01/21/20
11:29
Periodicals
Charges filed against Vale, TUV SUD for deadly dam collapse, WSJ reports »

Individuals at Vale and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$36.94

1.82 (5.18%)

11:28
01/21/20
01/21
11:28
01/21/20
11:28
Recommendations
Uber analyst commentary  »

Uber financial discipline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

LVS

Las Vegas Sands

$70.95

-3.12 (-4.21%)

11:25
01/21/20
01/21
11:25
01/21/20
11:25
Options
Las Vegas Sands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$0.39

-0.0109 (-2.73%)

11:25
01/21/20
01/21
11:25
01/21/20
11:25
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

11:25
01/21/20
01/21
11:25
01/21/20
11:25
Conference/Events
The National Economists Club to hold a luncheon meeting »

Gregory Daco, Chief U.S.…

11:25
01/21/20
01/21
11:25
01/21/20
11:25
Conference/Events
CFA Society of Columbus to hold luncheon meeting on 2020 fixed income »

Thomas Tzitzouris,…

INTC

Intel

$60.68

1.1 (1.85%)

, LB

L Brands

$20.40

0.24 (1.19%)

11:18
01/21/20
01/21
11:18
01/21/20
11:18
On The Fly
Intel, L Brands, Costco upgrades among today's top analyst calls »

Check out today's top…

INTC

Intel

$60.68

1.1 (1.85%)

LB

L Brands

$20.40

0.24 (1.19%)

COST

Costco

$311.46

6.78 (2.23%)

DG

Dollar General

$157.97

(0.00%)

LL

Lumber Liquidators

$8.46

-0.89 (-9.52%)

MS

Morgan Stanley

$55.51

-2 (-3.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 12

    Feb

  • 27

    Feb

  • 05

    Mar

LRCX

Lam Research

$311.12

3.14 (1.02%)

11:17
01/21/20
01/21
11:17
01/21/20
11:17
Recommendations
Lam Research analyst commentary  »

Lam Research price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
01/21/20
01/21
11:17
01/21/20
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
01/21/20
01/21
11:16
01/21/20
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COLM

Columbia Sportswear

$97.10

1.51 (1.58%)

, VFC

VF Corp.

$94.20

-0.05 (-0.05%)

11:15
01/21/20
01/21
11:15
01/21/20
11:15
Hot Stocks
Columbia Sportswear rises as VF Corp. review leads to speculation »

Shares of Columbia…

COLM

Columbia Sportswear

$97.10

1.51 (1.58%)

VFC

VF Corp.

$94.20

-0.05 (-0.05%)

KTB

Kontoor Brands

$42.31

0.595 (1.43%)

YETI

Yeti

$36.33

2.1 (6.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 06

    Feb

RCL

Royal Caribbean

$129.08

-5.96 (-4.41%)

11:15
01/21/20
01/21
11:15
01/21/20
11:15
Options
Royal Caribbean put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

11:15
01/21/20
01/21
11:15
01/21/20
11:15
General news
Treasury announced $80 B in 4- and 8-week bills for Thursday's auctions »

Treasury announced $80 B…

11:15
01/21/20
01/21
11:15
01/21/20
11:15
General news
U.S. equities opened with losses »

U.S. equities opened with…

11:15
01/21/20
01/21
11:15
01/21/20
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

11:15
01/21/20
01/21
11:15
01/21/20
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

11:15
01/21/20
01/21
11:15
01/21/20
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

11:15
01/21/20
01/21
11:15
01/21/20
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.